Geum-Youn Gwak1, Sung June Eo1, Su Rin Shin2, Moon Seok Choi1, Joon Hyoek Lee1, Kwang Cheol Koh1, Seung Woon Paik1, Byung Chul Yoo3,4. 1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 2. Department of Medicine, Kangnam Sacred Heart Hospital, Hallym University, Seoul, South Korea. 3. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. bc11.yoo@samsung.com. 4. Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710, South Korea. bc11.yoo@samsung.com.
Abstract
BACKGROUND: This study was undertaken to compare the efficacy, safety, and resistance profile of clevudine (CLV) and entecavir (ETV) following a 2-year treatment period. METHODS: One hundred and eight Korean patients from the prior 48-week study were followed with continuous therapy for up to 2 years and monitored for hepatitis B virus (HBV) DNA levels, HBeAg seroconversion, serum ALT, emergence of drug-resistant mutant HBV, and drug-related adverse events. RESULTS: A complete virological response during the 2-year treatment period occurred in 68.0 % in the CLV group and in 84.5 % in the ETV group (p = 0.043). The cumulative percentage of patients with sustained virological responses at 2 years was 54.0 and 77.6 % in the CLV and ETV group, respectively (p = 0.010). Virological breakthrough occurred in 12 patients in the CLV group; however, there were none in the ETV group (p < 0.001). HBeAg seroconversion rates were not different between the two groups. In patients who maintained sustained virological responses at 2 years, the mean reduction in HBsAg titer was -0.24 and -0.06 log IU/ml in the CLV and ETV group, respectively (p > 0.05). Clinical myopathy occurred in seven patients in the CLV group; however, this was not observed in the ETV group (p = 0.004). CONCLUSIONS: ETV was associated with a significantly higher virological response rate than CLV at 2 years. ETV was superior to CLV in terms of the drug resistance profile and the development of clinical myopathy. Further studies to see whether the unique characteristic of CLV to reduce HBsAg titer is associated with the removal of ccc-DNA from hepatocytes and the remission of the disease are needed.
BACKGROUND: This study was undertaken to compare the efficacy, safety, and resistance profile of clevudine (CLV) and entecavir (ETV) following a 2-year treatment period. METHODS: One hundred and eight Korean patients from the prior 48-week study were followed with continuous therapy for up to 2 years and monitored for hepatitis B virus (HBV) DNA levels, HBeAg seroconversion, serum ALT, emergence of drug-resistant mutant HBV, and drug-related adverse events. RESULTS: A complete virological response during the 2-year treatment period occurred in 68.0 % in the CLV group and in 84.5 % in the ETV group (p = 0.043). The cumulative percentage of patients with sustained virological responses at 2 years was 54.0 and 77.6 % in the CLV and ETV group, respectively (p = 0.010). Virological breakthrough occurred in 12 patients in the CLV group; however, there were none in the ETV group (p < 0.001). HBeAg seroconversion rates were not different between the two groups. In patients who maintained sustained virological responses at 2 years, the mean reduction in HBsAg titer was -0.24 and -0.06 log IU/ml in the CLV and ETV group, respectively (p > 0.05). Clinical myopathy occurred in seven patients in the CLV group; however, this was not observed in the ETV group (p = 0.004). CONCLUSIONS:ETV was associated with a significantly higher virological response rate than CLV at 2 years. ETV was superior to CLV in terms of the drug resistance profile and the development of clinical myopathy. Further studies to see whether the unique characteristic of CLV to reduce HBsAg titer is associated with the removal of ccc-DNA from hepatocytes and the remission of the disease are needed.
Authors: J H Kim; H J Yim; E S Jung; Y K Jung; J H Kim; Y S Seo; J E Yeon; H S Lee; S H Um; K S Byun Journal: J Viral Hepat Date: 2011-04 Impact factor: 3.728
Authors: Won Young Tak; Soo Young Park; Chang Min Cho; Min Kyu Jung; Seong Woo Jeon; Young Oh Kweon; Ji Young Park; Yoon Kyung Sohn Journal: J Hepatol Date: 2010-04-18 Impact factor: 25.083
Authors: Richard J Colonno; Ronald Rose; Carl J Baldick; Steven Levine; Kevin Pokornowski; Cheng F Yu; Ann Walsh; Jie Fang; Mayla Hsu; Charles Mazzucco; Betsy Eggers; Sharon Zhang; Mary Plym; Kenneth Klesczewski; Daniel J Tenney Journal: Hepatology Date: 2006-12 Impact factor: 17.425
Authors: Byung Kook Kim; Jeeyoung Oh; So Young Kwon; Won Hyeok Choe; Soon Young Ko; Kyoung Hoon Rhee; Tae Ho Seo; So Dug Lim; Chang Hong Lee Journal: J Hepatol Date: 2009-05-28 Impact factor: 25.083
Authors: Jung Im Seok; Dong Kuck Lee; Chang Hyeong Lee; Min Su Park; Sun Young Kim; Hyang-Sook Kim; Hee-Young Jo; Chang Hun Lee; Dae-Seong Kim Journal: Hepatology Date: 2009-06 Impact factor: 17.425
Authors: Hye Won Lee; Jun Yong Park; Beom Kyung Kim; Moon Young Kim; Jung Il Lee; Young Suk Kim; Ki Tae Yoon; Kwang-Hyub Han; Sang Hoon Ahn Journal: Clin Mol Hepatol Date: 2016-11-25
Authors: Soo Hyun Park; Kyung Seok Park; Nam Hee Kim; Joong Yang Cho; Moon Soo Koh; Jin Ho Lee Journal: J Korean Med Sci Date: 2017-11 Impact factor: 2.153